Clarification Memo #1 to:

HPTN 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men

Protocol Version 4.0, February 10, 2021

DAIDS Document ID: 20725

IND # 122, 744

Final Date of CM #1: March 3, 2021

Summary of Clarifications

The purpose of this Clarification Memo (CM) is to 1) provide operational instructions to sites regarding language included in the “Addendum To The Main Sample Informed Consent Form”; 2) correct a typographical error for oral CAB study product retrieval; and 3) clarify the resulting of safety assessments from previous visits.

The study Sponsor, the Division of AIDS (DAIDS) has determined that this CM should be implemented immediately upon issuance. Consistent with United States Food and Drug Administration guidance, institutional review board/ethics committee (IRB/EC) approval of this CM is not required by the Division of AIDS prior to implementation.

Please file this CM and any applicable IRB/EC correspondence in your regulatory document files for HPTN 083.

Implementation

1. The last page of the Addendum Consent Form in Appendix V of Version 4.0 of the protocol includes the highlighted sentence as follows:

   *Insert signature blocks as required by the local IRB:]* If you have read this addendum to the main consent form, or had it read and explained to you, and you understand the information, and you voluntarily agree to continue in this part of the study, please sign your name or make your mark below. Also, please indicate by providing your initials in the spaces below the additional sample collection, genetic testing, or long-term storage that you agree to.

   Additionally, the Version 3.0 to Version 4.0 Summary of Changes document states the following: “Note that re-consent for specimen storage and future research, genetic testing, and the DXA subset (where applicable) is not required.”

   While re-consent to these procedures is no longer a study requirement, sites should include the highlighted template language (or similar) in the site-specific addendum consent form if required by the IRB/EC/other regulatory entities, as well as adding corresponding signatures INITIALS (per IRB/EC other regulatory entity requirements. The language should be removed from the site-specific addendum consent form if it is not required or applicable.
2. Section 5 in Appendix V of Version 4.0 has a typographical error for study product preparation of CAB 30 mg Oral Product. Oral CAB 30mg tablet bottles are to be retrieved from the Step 1 supply:

   The pharmacist will take the following steps to prepare and dispense un-blinded active oral CAB to the participant:

   1) Retrieve oral active CAB 30mg tablet bottle with two part-label from Step 1 supply.

3. Section 7 in Appendix V of Version 4.0 includes a reference to safety visits. While safety visits are no longer conducted, all safety assessments from the previous visit must be resulted and protocol-allowable prior to administering the next injection:

   It is not required to contact the CMC for out of target window safety visits no matter when they occur; however, an injection visit or a study product dispensation visit may never be completed without preceding safety laboratory assessments being completed and all the assessments being resulted and protocol-allowable.